PFA 100 Evaluation and Reference Interval HOACNY

Part of paid clinical trials in East Syracuse, New York.

Sponsor
Hematology Oncology Associates of Central New York
Study ID
NCT06100510
Phase
PHASE4
Status
Enrolling By Invitation

Conditions

  • Effect of Drug

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Aspirin 325mg — DRUG
    Cohort B will receive one (1) 325 mg aspirin 24 hours prior to their second blood draw.

Study Details

The purpose of this research is to evaluate instrument functionality and develop a reference range of normal data by healthy volunteers.

Key Dates

Start date
Feb 19, 2024
Status verified
Oct 2024
Primary completion
Oct 10, 2024
Completion
Oct 10, 2024

Study Design

Enrollment
40 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING

Arms

  • No Intervention: Placebo (non-intervention) Arm
    Participants who will have PFA 100 testing performed without the ingestion of aspirin.
  • Active Comparator: Aspirin Arm
    Participants who will have PFA 100 testing performed after the ingestion of aspirin.

Primary Outcome Measure

Instrument Evaluation Protocol-PFA100 Instrumentation [platelet function as measured by aperture closure time monitored in seconds for collagen/epinephrine (COL/EPI) cartridges and collagen/ADP (COL/ADP) cartridges] [ Time Frame: 3 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Hematology Oncology Associates of Central New YorkEast SyracuseNew York13057-

Find similar trials in East Syracuse, NY

By research site
Hematology Oncology Associates of Central New York· East Syracuse, NY